Veru (NASDAQ:VERU) Announces Earnings Results, Beats Estimates By $0.15 EPS

Veru (NASDAQ:VERU) released its quarterly earnings data on Wednesday. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.15, Zacks reports. The business had revenue of $0.06 million during the quarter, compared to analysts’ expectations of $1.90 million.

Here are the key takeaways from Veru’s conference call:

• Veru highlighted positive Phase 2b QUALITY data for enobosarm plus semaglutide, saying it preserved lean mass and reduced the proportion of patients with a clinically significant decline in stair climb power versus semaglutide alone.
• The company said the 3 mg enobosarm arm produced a statistically significant 59.8% relative reduction in patients with at least a 10% decline in stair climb power, while the 6 mg arm showed a 44.1% relative reduction.
• Veru is now running the Phase 2b plateau study in older adults with obesity to test whether enobosarm can help patients break through the common GLP-1 weight-loss plateau and generate incremental weight loss while preserving function and bone health.
• Management said the first interim analysis for the plateau study is expected in Q1 calendar 2027, and that enrollment is progressing well and remains on track.
• Financially, Veru ended the quarter with $27.6 million in cash and restricted cash, and management said this should fund operations beyond the interim analysis. The quarterly net loss from continuing operations also improved to $3.1 million from $7.9 million a year ago.

Veru Stock Performance

NASDAQ VERU traded down $0.17 during trading hours on Thursday, hitting $2.09. 192,806 shares of the company’s stock were exchanged, compared to its average volume of 77,762. Veru has a 12-month low of $2.05 and a 12-month high of $7.40. The business’s 50 day moving average is $2.35 and its 200-day moving average is $2.46. The firm has a market capitalization of $33.54 million, a P/E ratio of -1.66 and a beta of -1.19.

Institutional Investors Weigh In On Veru

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Veru during the third quarter valued at approximately $38,000. XTX Topco Ltd acquired a new position in shares of Veru in the 2nd quarter worth approximately $49,000. ADAR1 Capital Management LLC acquired a new position in Veru in the fourth quarter worth $75,000. Blair William & Co. IL boosted its holdings in shares of Veru by 26.3% in the 4th quarter. Blair William & Co. IL now owns 48,000 shares of the company’s stock valued at $103,000 after buying an additional 10,000 shares during the period. Finally, Bank of America Corp DE grew its holdings in shares of Veru by 5.5% during the second quarter. Bank of America Corp DE now owns 185,669 shares of the company’s stock valued at $108,000 after purchasing an additional 9,637 shares during the last quarter. 47.16% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. Wall Street Zen lowered shares of Veru from a “hold” rating to a “sell” rating in a research report on Saturday, January 31st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Veru in a research report on Monday, April 20th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $22.50.

Trending Headlines about Veru

Here are the key news stories impacting Veru this week:

• Positive Sentiment: Veru reported a smaller-than-expected loss of ($0.13) per share, beating the consensus estimate of ($0.28), which suggests better cost control than analysts anticipated.
• Positive Sentiment: The company said its Phase 2b PLATEAU study of enobosarm + semaglutide is actively enrolling and remains on track for an interim analysis in Q1 2027, keeping its obesity pipeline moving forward.
• Positive Sentiment: Veru also reported improved cash resources, with cash, cash equivalents and restricted cash rising to $27.6 million from $15.8 million at the prior fiscal year-end, giving it more runway for development.
• Neutral Sentiment: Analysts at Canaccord Genuity maintained a cautious view, estimating Veru will lose $0.20 per share this quarter, while the full-year consensus remains at a ($1.43) loss per share.
• Negative Sentiment: Revenue came in at just $0.06 million, far below the $1.90 million consensus, highlighting the company’s limited near-term commercial sales.
• Negative Sentiment: Despite progress in the pipeline, Veru still posted an operating loss of $7.2 million for the quarter, underscoring continued dependence on external funding and future clinical success.

About Veru

Veru Inc is a clinical-stage biopharmaceutical company headquartered in Miami, Florida. The company is dedicated to the development and commercialization of novel therapies in the fields of oncology and infectious disease. Veru’s research strategy centers on advancing small-molecule and biologic candidates through clinical trials, leveraging its in-house manufacturing and formulation capabilities as well as strategic partnerships to support late-stage development.

The company’s lead product candidate is sabizabulin (VERU-111), an oral, microtubule-disrupting agent undergoing pivotal trials for indications that include metastatic castration-resistant prostate cancer and hospitalized patients with severe COVID-19.